Outcome measures in systemic sclerosis: An update on instruments and current research

[1]  M. Mayes,et al.  Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. , 2008, Arthritis and rheumatism.

[2]  R. Hays,et al.  Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. , 2007, Arthritis and rheumatism.

[3]  S. Antoniu.  Cyclophosphamide for scleroderma interstitial lung disease , 2007, Expert opinion on investigational drugs.

[4]  R. Hornung,et al.  Health values of patients with systemic sclerosis. , 2007, Arthritis and rheumatism.

[5]  D. Furst,et al.  Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test , 2006, Annals of the rheumatic diseases.

[6]  P. Merkel,et al.  Myofibroblasts and hyalinized collagen as markers of skin disease in systemic sclerosis. , 2006, Arthritis and rheumatism.

[7]  F. D'Ovidio,et al.  Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. , 2006, American journal of respiratory and critical care medicine.

[8]  P. Merkel,et al.  Durometry for the assessment of skin disease in systemic sclerosis. , 2006, Arthritis & Rheumatism.

[9]  M. Irwin,et al.  Single-factor scoring validation for the Health Assessment Questionnaire-Disability Index (HAQ-DI) in patients with systemic sclerosis and comparison with early rheumatoid arthritis patients , 2006, Quality of Life Research.

[10]  A. Gabrielli,et al.  Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. , 2006, The New England journal of medicine.

[11]  Charlie Strange,et al.  Cyclophosphamide versus placebo in scleroderma lung disease. , 2006, The New England journal of medicine.

[12]  C. Denton,et al.  Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. , 2006, European heart journal.

[13]  Richard W. Martin,et al.  Minimally important difference in diffuse systemic sclerosis: results from the d-penicillamine study , 2006, Annals of the rheumatic diseases.

[14]  A. Silman,et al.  Scleroderma--developing measures of response. , 2005, The Journal of rheumatology.

[15]  M. Böhm,et al.  Sildenafil in the Treatment of Raynaud’s Phenomenon Resistant to Vasodilatory Therapy , 2005, Circulation.

[16]  R. Hays,et al.  Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. , 2005, The Journal of rheumatology.

[17]  R. Elashoff,et al.  Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study. , 2005, Arthritis and rheumatism.

[18]  V. Steen.  Autoantibodies in systemic sclerosis. , 1996, Seminars in arthritis and rheumatism.

[19]  M. Mayes,et al.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. , 2004, Arthritis and rheumatism.

[20]  E. Kasarskis.  Disease‐modifying interventions , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.

[21]  A. Nicholson,et al.  CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. , 2004, Radiology.

[22]  R. Hesselstrand,et al.  Longitudinal development of skin involvement and reliability of high frequency ultrasound in systemic sclerosis , 2004, Annals of the rheumatic diseases.

[23]  R. Elashoff,et al.  Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. , 2004, Arthritis and rheumatism.

[24]  M. Mayes,et al.  Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial. , 2004, Arthritis and rheumatism.

[25]  Thomas R. Riley,et al.  A Randomized Double-blind Placebo-controlled Trial , 2004 .

[26]  T. Moore,et al.  Seventeen-point dermal ultrasound scoring system--a reliable measure of skin thickness in patients with systemic sclerosis. , 2003, Rheumatology.

[27]  M. Suarez‐Almazor,et al.  Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. , 2003, The Journal of rheumatology.

[28]  Richard W. Martin,et al.  Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. , 2002, Arthritis and rheumatism.

[29]  R. Barst,et al.  Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.

[30]  S. Rich,et al.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[31]  T. Hsieh,et al.  Effects of Cisapride on Oesophageal Transit of Solids in Patients with Progressive Systemic Sclerosis , 2002, Clinical Rheumatology.

[32]  P. Saldiva,et al.  Accuracy of high resolution CT in assessing idiopathic pulmonary fibrosis histology by objective morphometric index. , 2002, Pathology, research and practice.

[33]  N. Bellamy,et al.  A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. , 2001, Arthritis and rheumatism.

[34]  Richard W. Martin,et al.  Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. , 2000, Arthritis and rheumatism.

[35]  L. Moreland,et al.  Recombinant Human Relaxin in the Treatment of Scleroderma , 2000, Annals of Internal Medicine.

[36]  R. Ciconelli,et al.  Evaluation of the short-form 36-item questionnaire to measure health-related quality of life in patients with idiopathic pulmonary fibrosis. , 2000, Chest.

[37]  Stuart Rich,et al.  Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.

[38]  M. Fujita,et al.  Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.

[39]  A. Blann,et al.  Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. , 1999, Arthritis and rheumatism.

[40]  Richard W. Martin,et al.  High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. , 1999, Arthritis and rheumatism.

[41]  P. Tugwell,et al.  The OMERACT filter for Outcome Measures in Rheumatology. , 1998, The Journal of rheumatology.

[42]  A. Silman,et al.  Assessment of functional ability in patients with scleroderma: a proposed new disability assessment instrument. , 1998, The Journal of rheumatology.

[43]  T. Medsger,et al.  The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. , 1997, Arthritis and rheumatism.

[44]  F. Martinez,et al.  Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. , 1997, AJR. American journal of roentgenology.

[45]  R. Sjogren.  Gastrointestinal features of scleroderma. , 1996, Current opinion in rheumatology.

[46]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.

[47]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[48]  Richard W. Martin,et al.  Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. , 1995, The Journal of rheumatology.

[49]  P. Lachenbruch,et al.  Guidelines for clinical trials in systemic sclerosis (scleroderma). I. Disease-modifying interventions. The American College of Rheumatology Committee on Design and Outcomes in Clinical Trials in Systemic Sclerosis. , 1995, Arthritis and rheumatism.

[50]  T. Medsger,et al.  Severe restrictive lung disease in systemic sclerosis. , 1994, Arthritis and rheumatism.

[51]  T. Horikoshi,et al.  Effect of H2-receptor antagonists cimetidine and famotidine on interdigestive gastric motor activity and lower esophageal sphincter pressure in progressive systemic sclerosis. , 1994, Internal medicine.

[52]  L. Kaufman,et al.  Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study , 1994, Annals of Internal Medicine.

[53]  D. Bloch,et al.  Predictors of survival in systemic sclerosis (scleroderma). , 1991, Arthritis and rheumatism.

[54]  C. Wells,et al.  The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. , 1984, Chest.

[55]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[56]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.